Editorial Credits/ Crédits éditorials

CLINICAL PRACTICE GUIDELINES
Treatment of Schizophrenia
(Complete PDF)

Contents
(PDF)

I. Introduction
(PDF)

II. Assessments
(PDF)

III. Pharmacotherapy
(PDF)

IV. Psychosocial Interventions
(PDF)

V. Service Delivery
(PDF)

VI. Special Issues (PDF)

List of Abbreviations (PDF)

Bibiliography
(PDF)

Appendices
(PDF)

Acknowledgements

CLINICAL PRACTICE GUIDELINES Treatment of Schizophrenia

Acknowledgements

The authors thank Marie-France Demers and Julie Villeneuve for their contributions to the Pharmacotherapy section. We also thank Emily Mckenzie, who coordinated the literature review and the rating of individual articles.

We also thank the many external international and Canadian reviewers who took the time to provide valuable comments on a draft of this guideline.

The development, printing, and distribution of these guidelines was made possible through the CPA CPG Fund, to which each of the following companies made equal, arm’s-length, unrestricted grants:

AstraZeneca Canada Inc.
Eli Lilly Canada Inc.
Janssen-Ortho Inc.
Pfizer Canada Inc.